Likewise, the correlation between KRAS and glycolysis was further reinforced by immunostaining analysis in CRC tissues, which revealed that tumors with mutant KRAS had a higher expression of tumor glycolytic enzymes, including GLUT1, GLUT3, and HK2, than the tumors with wild-type KRAS (Supplementary Fig. 2n, o). Here, SLC2A1 is linked to colorectal carcinoma.